DF Dent & Co. Inc. Trims Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

DF Dent & Co. Inc. cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 53,272 shares of the company’s stock after selling 941 shares during the period. DF Dent & Co. Inc. owned 0.07% of IDEXX Laboratories worth $22,025,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of IDXX. FMR LLC increased its position in IDEXX Laboratories by 3.6% in the 3rd quarter. FMR LLC now owns 290,861 shares of the company’s stock valued at $146,949,000 after acquiring an additional 10,017 shares during the period. Quantbot Technologies LP purchased a new position in IDEXX Laboratories during the 3rd quarter worth $341,000. Public Sector Pension Investment Board raised its position in IDEXX Laboratories by 16.2% during the 3rd quarter. Public Sector Pension Investment Board now owns 3,578 shares of the company’s stock worth $1,808,000 after buying an additional 500 shares during the last quarter. Verition Fund Management LLC lifted its stake in shares of IDEXX Laboratories by 20.5% in the 3rd quarter. Verition Fund Management LLC now owns 6,508 shares of the company’s stock worth $3,288,000 after acquiring an additional 1,108 shares during the period. Finally, Erste Asset Management GmbH purchased a new stake in shares of IDEXX Laboratories in the third quarter valued at about $1,428,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on IDXX. Morgan Stanley cut their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, March 25th. Barclays upped their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Finally, Piper Sandler upped their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Trading Up 1.8 %

NASDAQ:IDXX opened at $426.25 on Thursday. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $548.88. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The stock has a fifty day simple moving average of $436.82 and a 200-day simple moving average of $441.34. The company has a market capitalization of $34.55 billion, a PE ratio of 39.95, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39.

Insiders Place Their Bets

In other news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.